Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives
Nova Mentis Receives Controlled Substances Export Approval From The U.S DEA For The Company’s Proprietary
Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08
Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08
Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study Study
Nova Mentis Welcomes Autism Behaviour Analyst to its Science Team Vancouver, British Columbia – May 12,
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults COMPASS Pathways (CMPS) is
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine
If you’ve been wanting to try psychedelic therapy legally, now’s your chance! Johns Hopkins is
Nova Mentis Sees Rapid Enrollment in Autism Study Databank to focus on mRNA neuroinflammatory markers
Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder Wesana Health (WESA)
Nova Mentis to Produce Psilocybin Capsules for Phase 2A Clinical Study Manufacturing Contract with the
Core One Labs’ Akome Receives Positive Results from Bioassay Studies Will Look to Advance its
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease The most
Nova Mentis Begins Enrollment in North American Autism Study Vancouver, British Columbia – March 23, 2022 – Nova
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease 100% of
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant CHICAGO and TORONTO,
Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013 Pre-IND Meeting is
Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program Tripping on ibogaine can last over
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism Vancouver, British Columbia – February 16,
Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its
Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy
Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin
